We propose that this model provides greater translational relevance for the evaluation of local treatments of incisional pain compared with existing rodent models of incisional pain
St Paul, MN (PRWEB) September 25, 2013
MD Biosciences article "Characterization of a porcine model of post-operative pain" is published in the September 2013 issue of European Journal of Pain. Dr Sigal Meilin, lead neuroscientist and research director at MD Biosciences along with colleagues developed and published a large in vivo model of post-operative pain (POP) that provides greater translational relevance for the evaluation of local treatments of POP compared with existing rodent models of incisional pain.
The management of acute pain related to surgical intervention, termed post-operative pain, continues to be a major healthcare challenge. Historically the rodent has been the model of choice for developing new analgesic treatments in the study of POP. One of the major disadvantages of the rodent model is its limited use in assessing topical and localized treatments. The anatomy of the rodent skin is also significantly different from human skin and healing occurs primarily by wound contraction rather than re-epithelialization. Porcine skin on the other hand has a higher degree of homology to human skin and heals by epidermal cell migration. There is also a considerable correlation between contracile, metabolic and morphological features in skeletal muscle of humans and pigs. The pigskin is also tightly attached to the muscle and subcutaneous tissue as in humans.
We have developed a model of post-operative pain utilizing full-skin incision or full skin and muscle incision and retraction (SIMR). We propose that this model provides greater translational relevance for local treatments compared to rodent models and enables three important parameters to be assessed in parallel:
- Nociceptive sensitivity
- Spontaneous behavior
- Wound healing and inflammation
MD Biosciences research group is actively involved in developing approaches, methods and models that bring greater translational relevance to the clinical situation. With greater than 90% failure rate in the clinical trial phase of drug development, more relevant models are needed that provide greater translation to the clinic. More information about the preclinical models of pain offered at MD Biosciences or access the European Journal of Pain article can be found on MD Biosciences website.
About MD Biosciences
MD Biosciences is a leading preclinical research group and contract research organization (CRO) working with biopharmaceutical and medical device companies in an effort towards progressing discovery and development programs to clinical stages. We are deeply focused on inflammatory, neurodegenerative/CNS, pain, dermal, metabolic and cardiovascular conditions with a particular emphasis on the interplay between the immune, nervous and cardiovascular systems and the conditions that arise in the cross talk between them. We bring decisive value to preclinical programs with the extensive experience gained over many years of handling different compound classes through all administration routes aimed at numerous therapeutic indications.
The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.